The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Biologics in Rheumatology: Revolution & Perspectives

Biologics in Rheumatology: Revolution & Perspectives

December 8, 2020 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2020—Gerd Burmester, MD, professor of medicine at Charité, University Medicine, Berlin, gave this year’s Phillip Hench, MD, Memorial Lecture and used the opportunity to review the evolution of the treatment of rheumatic diseases with a focus on biologics.

You Might Also Like
  • DMARDs & Biologics Info for Rheumatology Nurses
  • The American College of Rheumatology Helps Keep Three Biologics Off the SAD List
  • When Starting Biologics for RA, Disease Severity Predicts Likelihood of Remission
Also By This Author
  • IL-26 Plays Antimicrobial Role in Immune Response

Dr. Burmester described four milestones in treatment evolution, starting by outlining how glucocorticoids, one of the first drugs used to treat rheumatic disease, continue to play an important role in rheumatology. Glucocorticoids not only help with pain relief, but also modify disease in early rheumatoid arthritis (RA) and are immunosuppressive in vasculitides and systemic lupus erythematosus (SLE). Patients are more likely to experience adverse effects with longer use and higher doses of glucocorticoids.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The next milestone, methotrexate, joined glucocorticoids as a treatment for RA when rheumatologists prescribed it to reduce disease activity. Methotrexate’s dramatic effect on the lives of patients has made it the most popular drug worldwide for the treatment of RA. Low-dose methotrexate administered weekly can be used as a monotherapy and, for some patients, can be as effective as the newer biologics, especially in combination with glucocorticoids. Although methotrexate monotherapy may reduce radiographic progression in RA, some patients experience this positive effect, which can potentially abolish radiologic changes, only when methotrexate is combined with biologic therapies.

These biologic therapies, or biologics, have taken a prominent place in the RA treatment arsenal. The numerous current therapies include B cell inhibitors, interleukin (IL) 1 blockers, IL-6 blockers and, most notably, tumor necrosis factor (TNF) inhibitors. Initially, rheumatologists recognized CD4-positive cells are important in the pathophysiology of disease, and thus, the first biologic to be used for the treatment of RA was anti-CD4.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In 1991, Dr. Burmester and colleagues published the results of a series of 10 patients with severe intractable RA treated with a monoclonal antibody (known as 16H5) against the CD4 antigen present on T helper cells.1 In the open trial, they infused the monoclonal antibody and documented its clinical benefits. They noted in their paper that it remained to be determined whether long-term remission could be induced with this therapeutic approach.

A few years later, investigators created a chimeric CD4 monoclonal antibody called cM-T412 and evaluated its use in RA patients. In initial results, patients tended to demonstrate a favorable clinical response; however, a subsequent controlled clinical trial did not show a benefit.

ACR Convergence graphicAlemtuzumab (CAMPATH-IH) was among the first humanized, therapeutic, monoclonal antibodies and, thus, the first of many targeted immunomodulatory therapies that have revolutionized the treatment of autoimmune diseases. Alemtuzumab depletes cells expressing CD52 (T and B cells, monocytes and natural killer cells). In the early 1990s, alemtuzumab was successfully used to treat patients with refractory RA. Unfortunately, however, many patients experienced profound lymphopenia, especially in the CD4+ compartment, and alemtuzumab fell out of favor as a treatment for RA.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Biologics & Biosimilars, Meeting Reports Tagged With: ACR Convergence 2020, biologic drugs, Biologics, Biosimilars, meeting reports

You Might Also Like:
  • DMARDs & Biologics Info for Rheumatology Nurses
  • The American College of Rheumatology Helps Keep Three Biologics Off the SAD List
  • When Starting Biologics for RA, Disease Severity Predicts Likelihood of Remission
  • EULAR 2014: Non-Tumor Necrosis Factor Biologics Update

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.